Overview

TD-1607 MAD Study in Healthy Subjects

Status:
Completed

Trial end date:
2014-07-01

Target enrollment:

Participant gender:

Summary

TD-1607, administered intravenously as multiple ascending doses, will be investigated in healthy subjects to assess its tolerability, safety, and pharmacokinetics.

Phase:

Phase 1

Details

Lead Sponsor:

Theravance Biopharma
Theravance Biopharma Antibiotics, Inc.